Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.75 |
| ▸ | GCGR | P47871 | 13/20 | 0.75 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.67 |
| ▸ | RAF1 | P04049 | 2/20 | 0.67 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.67 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.67 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.67 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2647090 | 1.00 | MAPK14 (0.75) | MAPK14GCGRMAPK13RAF1MAPK9 | |
| SCHEMBL8119445 | 1.00 | MAPK14 (0.75) | MAPK14GCGRMAPK13RAF1MAPK9 | |
| SCHEMBL8318877 | 0.89 | GCGR (0.66) | MAPK14GCGR | |
| SCHEMBL2662559 | 0.87 | GCGR (1.00) | MAPK14GCGRMAPK13RAF1MAPK9 | |
| SCHEMBL2647264 | 0.85 | MAPK14 (0.77) | MAPK14GCGRMAPK13RAF1MAPK9 | |
| SCHEMBL2647604 | 0.80 | GCGR (1.00) | MAPK14GCGR | |
| SCHEMBL6586611 | 0.80 | GCGR (0.86) | MAPK14GCGR | |
| SCHEMBL8325229 | 0.80 | MAPK14 (1.00) | MAPK14GCGRMAPK13RAF1MAPK9 | |
| SCHEMBL2647609 | 0.80 | GCGR (0.79) | MAPK14GCGRMAPK13RAF1MAPK9 | |
| SCHEMBL21557189 | 0.80 | GCGR (1.00) | MAPK14GCGRMAPK13RAF1MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170095462-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. | 2017-04-06 | — | — | US | disclosed |
| US-9527816-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9290450-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-8969347-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. | 2015-03-03 | — | — | US | disclosed |
| US-20140228310-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8748666-B2 | Preparation methods of methyl-D3-amine and salts thereof | SUZHOU ZELGEN BIOPHARMACEUTICAL CO., LTD. (CN) | 2014-06-10 | — | — | US | disclosed |
| US-8741936-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130102597-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-8304413-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304413-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120258924-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20100240704-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. | 2010-09-23 | — | — | US | disclosed |
| US-20100240704-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. | 2010-09-23 | — | — | US | disclosed |
| US-7728013-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728013-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240704-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | MAPKAPK2, MAP3K6, MAP4K1 | MAPK14 36/4885GCGR 4001/4885MAPK13 37/4885 |
| US-20130102597-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | MAP3K8, MAP3K1, MAP3K6 | MAPK14 43/4885GCGR 3849/4885MAPK13 41/4885 |
| US-20170095462-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | MAPKAPK2, MAP3K6, MAP4K1 | MAPK14 36/4885GCGR 4001/4885MAPK13 37/4885 |
| US-20140228310-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | MAPKAPK2, MAP3K6, MAP4K1 | MAPK14 36/4885GCGR 4001/4885MAPK13 37/4885 |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | MAP3K8, MAP3K1, MAP3K6 | MAPK14 43/4885GCGR 3849/4885MAPK13 41/4885 |
| US-20120258924-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | MAPKAPK2, MAP3K6, MAP4K1 | MAPK14 36/4885GCGR 4001/4885MAPK13 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.